First Time Loading...
F

Fujian Aonong Biological Technology Group Incorporation Ltd
SSE:603363

Watchlist Manager
Fujian Aonong Biological Technology Group Incorporation Ltd
SSE:603363
Watchlist
Price: 4.24 CNY 3.67% Market Closed
Updated: May 19, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

13.6B
-18%
Assets
Growth Rates:
1 Year
-27%
3 Years
+13%
5 Years
+312%
7 Years
+696%
10 Years
-
14.6B
-6%
Liabilities
Growth Rates:
1 Year
-10%
3 Years
+57%
5 Years
+486%
7 Years
+1 077%
10 Years
-
-963m
Equity
Growth Rates:
1 Year
-
3 Years
-
5 Years
-
7 Years
-
10 Years
-

Balance Sheet Decomposition
Fujian Aonong Biological Technology Group Incorporation Ltd

13.6B
Assets
14.6B
Liabilities
13.6B
Assets
14.6B
Liabilities
Current Assets 2.8B
Cash & Short-Term Investments 155.4m
Receivables 925.5m
Other Current Assets 1.7B
Non-Current Assets 10.8B
Long-Term Investments 344.6m
PP&E 8.7B
Intangibles 810.7m
Other Non-Current Assets 949.1m
Current Liabilities 11.4B
Accounts Payable 3.4B
Accrued Liabilities 394.8m
Short-Term Debt 5.1B
Other Current Liabilities 2.5B
Non-Current Liabilities 3.2B
Long-Term Debt 2.6B
Other Non-Current Liabilities 675m

Balance Sheet
Fujian Aonong Biological Technology Group Incorporation Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
89
193
174
229
121
255
571
444
623
151
Cash
0
0
0
0
0
0
0
444
623
151
Cash Equivalents
89
193
174
229
121
255
571
0
0
0
Short-Term Investments
0
0
0
100
0
0
1
1
3
5
Total Receivables
205
292
299
399
587
575
777
816
784
925
Accounts Receivables
163
267
265
342
482
427
449
527
515
648
Other Receivables
42
25
34
57
105
148
328
289
269
277
Inventory
242
243
285
392
433
599
1 731
2 589
3 289
1 328
Other Current Assets
19
24
43
57
84
85
444
413
418
380
Total Current Assets
555
751
802
1 177
1 226
1 514
3 524
4 263
5 115
2 789
PP&E Net
219
415
689
1 046
1 604
2 664
6 775
10 890
11 116
8 732
PP&E Gross
0
0
689
1 046
1 604
2 664
6 775
10 890
11 116
8 732
Accumulated Depreciation
0
0
88
152
223
356
866
1 728
2 712
3 498
Intangible Assets
43
72
100
143
177
207
374
463
651
424
Goodwill
4
6
10
15
21
136
455
489
439
386
Long-Term Investments
5
6
17
24
87
87
222
190
320
345
Other Long-Term Assets
100
98
94
133
191
314
667
806
1 018
949
Other Assets
4
6
10
15
21
136
455
489
439
386
Total Assets
927
N/A
1 348
+45%
1 712
+27%
2 538
+48%
3 305
+30%
4 922
+49%
12 019
+144%
17 101
+42%
18 661
+9%
13 625
-27%
Liabilities
Accounts Payable
355
476
491
540
726
1 324
2 121
3 678
3 951
3 422
Accrued Liabilities
31
35
37
44
63
69
208
342
409
395
Short-Term Debt
177
208
241
436
938
1 380
2 921
4 286
4 661
5 056
Current Portion of Long-Term Debt
8
27
58
82
89
310
166
1 083
1 620
1 642
Other Current Liabilities
128
126
124
125
166
299
832
727
1 005
845
Total Current Liabilities
698
872
951
1 228
1 982
3 382
6 248
10 117
11 645
11 359
Long-Term Debt
0
0
148
307
288
108
1 919
4 638
3 409
2 554
Deferred Income Tax
0
0
0
0
5
7
23
26
24
19
Minority Interest
44
64
121
157
195
456
1 161
890
928
460
Other Liabilities
14
31
19
38
21
142
75
127
151
196
Total Liabilities
756
N/A
967
+28%
1 239
+28%
1 730
+40%
2 491
+44%
4 094
+64%
9 277
+127%
15 797
+70%
16 157
+2%
14 588
-10%
Equity
Common Stock
100
300
360
420
426
434
674
684
871
870
Retained Earnings
55
54
85
193
208
234
755
867
1 906
5 556
Additional Paid In Capital
15
28
28
195
218
257
1 483
1 535
3 664
3 776
Unrealized Security Profit/Loss
0
0
0
0
0
0
0
39
43
37
Treasury Stock
0
0
0
0
39
76
147
159
82
17
Other Equity
0
0
0
0
0
21
23
149
0
0
Total Equity
171
N/A
381
+123%
473
+24%
808
+71%
814
+1%
828
+2%
2 742
+231%
1 303
-52%
2 504
+92%
963
N/A
Total Liabilities & Equity
927
N/A
1 348
+45%
1 712
+27%
2 538
+48%
3 305
+30%
4 922
+49%
12 019
+144%
17 101
+42%
18 661
+9%
13 625
-27%
Shares Outstanding
Common Shares Outstanding
130
390
468
546
554
564
674
684
858
868

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.